Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-24-068041
Filing Date
2024-03-14
Accepted
2024-03-14 17:21:12
Documents
10

Document Format Files

Seq Description Document Type Size
1 S-3 d780013ds3.htm S-3 398689
2 EX-4.6 d780013dex46.htm EX-4.6 295019
3 EX-4.9 d780013dex49.htm EX-4.9 93121
4 EX-4.10 d780013dex410.htm EX-4.10 94841
5 EX-4.11 d780013dex411.htm EX-4.11 82790
6 EX-5.1 d780013dex51.htm EX-5.1 27278
7 EX-23.1 d780013dex231.htm EX-23.1 1709
8 EX-FILING FEES d780013dexfilingfees.htm EX-FILING FEES 79966
9 GRAPHIC g780013g0313115758336.jpg GRAPHIC 2534
10 GRAPHIC g780013g50x50.jpg GRAPHIC 47450
  Complete submission text file 0001193125-24-068041.txt   1139351
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-277951 | Film No.: 24751323
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)